Access to sexual and reproductive health commodities in East and Southern Africa: a cross-country comparison of availability, affordability and stock-outs in Kenya, Tanzania, Uganda and Zambia.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
03 Jul 2020
Historique:
received: 03 03 2020
accepted: 19 06 2020
entrez: 5 7 2020
pubmed: 6 7 2020
medline: 26 11 2020
Statut: epublish

Résumé

Access to sexual and reproductive health services continues to be a public health concern in Kenya, Tanzania, Uganda and Zambia: use of modern contraceptives is low, and unmet family planning needs and maternal mortality remain high. This study is an assessment of the availability, affordability and stock-outs of essential sexual and reproductive health commodities (SRHC) in these countries to inform interventions to improve access. The study consisted of an adaptation of the World Health Organization/Health Action International methodology, Measuring Medicine Prices, Availability, Affordability and Price Components. Price, availability and stock-out data was collected in July 2019 for over fifty lowest-priced SRHC from public, private and private not-for-profit health facilities in Kenya (n = 221), Tanzania (n = 373), Uganda (n = 146) and Zambia (n = 245). Affordability was calculated using the wage of a lowest-paid government worker. Accessibility was illustrated by combining the availability (≥ 80%) and affordability (less than 1 day's wage) measures. Overall availability of SRHC was low at less than 50% in all sectors, areas and countries, with highest mean availability found in Kenyan public facilities (46.6%). Stock-outs were common; the average number of stock-out days per month ranged from 3 days in Kenya's private and private not-for-profit sectors, to 12 days in Zambia's public sector. In the public sectors of Kenya, Uganda and Zambia, as well as in Zambia's private not-for-profit sector, all SRHC were free for the patient. In the other sectors unaffordability ranged from 2 to 9 SRHC being unaffordable, with magnesium sulphate being especially unaffordable in the countries. Accessibility was low across the countries, with Kenya's and Zambia's public sectors having six SRHC that met the accessibility threshold, while the private sector of Uganda had only one SRHC meeting the threshold. Accessibility of SRHC remains a challenge. Low availability of SRHC in the public sector is compounded by regular stock-outs, forcing patients to seek care in other sectors where there are availability and affordability challenges. Health system strengthening is needed to ensure access, and these findings should be used by national governments to identify the gaps and shortcomings in their supply chains.

Sections du résumé

BACKGROUND BACKGROUND
Access to sexual and reproductive health services continues to be a public health concern in Kenya, Tanzania, Uganda and Zambia: use of modern contraceptives is low, and unmet family planning needs and maternal mortality remain high. This study is an assessment of the availability, affordability and stock-outs of essential sexual and reproductive health commodities (SRHC) in these countries to inform interventions to improve access.
METHODS METHODS
The study consisted of an adaptation of the World Health Organization/Health Action International methodology, Measuring Medicine Prices, Availability, Affordability and Price Components. Price, availability and stock-out data was collected in July 2019 for over fifty lowest-priced SRHC from public, private and private not-for-profit health facilities in Kenya (n = 221), Tanzania (n = 373), Uganda (n = 146) and Zambia (n = 245). Affordability was calculated using the wage of a lowest-paid government worker. Accessibility was illustrated by combining the availability (≥ 80%) and affordability (less than 1 day's wage) measures.
RESULTS RESULTS
Overall availability of SRHC was low at less than 50% in all sectors, areas and countries, with highest mean availability found in Kenyan public facilities (46.6%). Stock-outs were common; the average number of stock-out days per month ranged from 3 days in Kenya's private and private not-for-profit sectors, to 12 days in Zambia's public sector. In the public sectors of Kenya, Uganda and Zambia, as well as in Zambia's private not-for-profit sector, all SRHC were free for the patient. In the other sectors unaffordability ranged from 2 to 9 SRHC being unaffordable, with magnesium sulphate being especially unaffordable in the countries. Accessibility was low across the countries, with Kenya's and Zambia's public sectors having six SRHC that met the accessibility threshold, while the private sector of Uganda had only one SRHC meeting the threshold.
CONCLUSIONS CONCLUSIONS
Accessibility of SRHC remains a challenge. Low availability of SRHC in the public sector is compounded by regular stock-outs, forcing patients to seek care in other sectors where there are availability and affordability challenges. Health system strengthening is needed to ensure access, and these findings should be used by national governments to identify the gaps and shortcomings in their supply chains.

Identifiants

pubmed: 32620159
doi: 10.1186/s12889-020-09155-w
pii: 10.1186/s12889-020-09155-w
pmc: PMC7333276
doi:

Substances chimiques

Drugs, Essential 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1053

Subventions

Organisme : Ministerie van Buitenlandse Zaken
ID : 27542
Organisme : Ministerie van Buitenlandse Zaken
ID : 27542
Organisme : Ministerie van Buitenlandse Zaken
ID : 27542
Organisme : Ministerie van Buitenlandse Zaken
ID : 27542

Références

BMC Pregnancy Childbirth. 2009 Mar 04;9:10
pubmed: 19261181
Contraception. 2019 Apr;99(4):205-211
pubmed: 30685286
Health Policy. 2005 Aug;73(2):127-38
pubmed: 15978956
BMJ Glob Health. 2019 Oct 05;4(Suppl 9):e001306
pubmed: 31673436
Int Fam Plan Perspect. 2007 Mar;33(1):13-21
pubmed: 17462984
Lancet. 2009 Jan 17;373(9659):240-9
pubmed: 19042012
BMC Health Serv Res. 2010 Dec 16;10:340
pubmed: 21162717
J Glob Health. 2017 Dec;7(2):021101
pubmed: 29163936
Reprod Health. 2014 Jan 02;11(1):1
pubmed: 24383405
J Pharm Policy Pract. 2017 Nov 15;10:35
pubmed: 29163976
Bull World Health Organ. 2010 Apr;88(4):243-4
pubmed: 20431781
Rev Panam Salud Publica. 2010 Apr;27(4):291-9
pubmed: 20512232
Trans R Soc Trop Med Hyg. 2008 Nov;102(11):1067-74
pubmed: 18565559
Global Health. 2012 Jul 02;8:22
pubmed: 22747646
Contraception. 2014 Jun;89(6):564-71
pubmed: 24630244
PLoS Med. 2010 Jun 21;7(6):e1000295
pubmed: 20574515
J Adolesc Health. 2015 Jan;56(1 Suppl):S22-41
pubmed: 25528977
Value Health. 2012 Jul-Aug;15(5):664-73
pubmed: 22867775
PLoS Med. 2011 Jan 25;8(1):e1000394
pubmed: 21283606
BMC Pregnancy Childbirth. 2012 Jan 26;12:6
pubmed: 22280163
Lancet. 2006 Nov 4;368(9547):1595-607
pubmed: 17084760
Int J Gynaecol Obstet. 2015 Oct;131 Suppl 1:S40-2
pubmed: 26433504
Health Policy Plan. 2012 Mar;27 Suppl 1:i46-54
pubmed: 22388500
PLoS One. 2017 Feb 7;12(2):e0171284
pubmed: 28170413
BMC Health Serv Res. 2018 May 31;18(1):390
pubmed: 29855292
BMC Pregnancy Childbirth. 2018 Aug 23;18(1):346
pubmed: 30139342
Glob Health Sci Pract. 2016 Dec 28;4(4):647-660
pubmed: 28031302
Epilepsia. 2012 Jun;53(6):962-9
pubmed: 22432967
BMC Health Serv Res. 2013 Feb 14;13:61
pubmed: 23410228
Contraception. 2011 May;83(5):486-90
pubmed: 21477694
Lancet Glob Health. 2015 Dec;3(12):e733-4
pubmed: 26545447

Auteurs

Gaby I Ooms (GI)

Health Action International, Overtoom 60-2, 1054, HK, Amsterdam, The Netherlands. gaby@haiweb.org.
WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands. gaby@haiweb.org.

Denis Kibira (D)

WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.
Coalition for Health Promotion and Social Development (HEPS-Uganda), Kampala, Uganda.

Tim Reed (T)

Health Action International, Overtoom 60-2, 1054, HK, Amsterdam, The Netherlands.

Hendrika A van den Ham (HA)

WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.

Aukje K Mantel-Teeuwisse (AK)

WHO Collaborating Centre for Pharmaceutical Policy and Regulation, Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Utrecht, The Netherlands.

Gemma Buckland-Merrett (G)

Wellcome Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH